受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
製品コード:A2022 Batch: A202202
Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response.
CAS No. | 1801342-60-8 |
---|---|
Formulation | PBS buffer. Contains no stabilizers or preservatives |
Isotype | Human IgG4 |
Source | HEK293 |
Storage (From the date of receipt) |
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles |
Shipping | Shipped under low temperature conditions |
Purity | 99% |
Protein concentration | 4.3 mg/ml |
Endotoxin Level | <1 EU/mg |
Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors [ Life Sci Alliance, 2024, 7(3)e202302368] | PubMed: 38176728 |
人間や獣医の診断であるか治療的な使用のためにでない。